Neurizon has been on a bit of a journey this year, and as a consequence are in an interesting spot if you like a good pharmaceutical speculation. They are finally about to commence in the Healey ALS Platform trial, and are in the middle of scraping together equity funds to see them through it, as required.

The Healey ALS Platform is not your average trial, it is a head-to-head multi-round trial set up for the ALS community to efficiently and ethically identify their best candidates by running multiple candidates all sharing a placebo group. Should Neurizon emerge showing the same improved survival and biomarker signal as it has already shown on a small number of patients, then things should get interesting at the other end.

Webinar will be worth a listen.